Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on a Phase 1/2 sub-study evaluating belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Nirogacestat (nirogacestat)
• Revlimid (lenalidomide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING